ストックスクリーナーアプリを入手
1.56
3.11%
-0.05
アフターアワーズ：
1.53
-0.03
-1.92%
Fortress Biotech Inc (FBIO) 最新ニュース
Fortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Fortress Biotech Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
Fortress Biotech Transforms Portfolio: Dual FDA Wins, $28M Deal, Latest Earnings - Stock Titan
Fortress Biotech, Inc. (NASDAQ:FBIO) Q4 2024 Earnings Call Transcript - Insider Monkey
Fortress Biotech’s Mixed Earnings Call: Emrosi’s Launch and Challenges - TipRanks
Breakthrough: CKPT Secures FDA Approval and $416M Merger Deal in Transformative Year - Stock Titan
MUSTANG BIO, INC. SEC 10-K Report - TradingView
Journey Medical Reports 2024 Financial Results - TipRanks
FDA Green Light for Journey Medical's Rosacea Drug Reshapes 2024 Performance - StockTitan
Fortress Biotech Inc (FBIO) Q4 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus
Fortress Biotech (NASDAQ:FBIOP) Trading Up 3.9% – Here’s Why - Defense World
Fortress Biotech (FBIO) Expected to Announce Earnings on Thursday - Defense World
Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025 - GlobeNewswire
Journey Medical Sets Date for 2024 Annual Results: Dermatology Leader's Financial Update - Stock Titan
Atria Investments Inc Buys 16,841 Shares of Fortress Biotech, Inc. (NASDAQ:FBIO) - Defense World
Partex And Fortress Biotech Announce Collaboration To Accelerate Biopharma Asset Evaluation - Nasdaq
Fortress Biotech, Partex Team Up for Asset Identification, Evaluation Using AI -March 17, 2025 at 09:36 am EDT - Marketscreener.com
Fortress Biotech partners with Partex for AI-driven drug discovery By Investing.com - Investing.com Australia
Fortress Biotech partners with Partex for AI-driven drug discovery - Investing.com
Partex NV and Fortress Biotech, Inc. Announce Strategic Collaboration to Leverage AI in Biopharmaceutical Drug Discovery - Nasdaq
Partex and Fortress Biotech Announce Strategic - GlobeNewswire
AI Breakthrough: Fortress Biotech's New Partnership Transforms Drug Development Process - StockTitan
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
Equities Analysts Offer Predictions for FBIO Q1 Earnings - Defense World
Fortress Biotech (NASDAQ:FBIO) Receives “Buy” Rating from Roth Mkm - Defense World
Benign Growth For Fortress Biotech, Inc. (NASDAQ:FBIO) Underpins Its Share Price - Simply Wall St
CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun Pharma - Longview News-Journal
Lake Street Downgrades Checkpoint Therapeutics to Hold From Buy, $4.10 Price Target - Marketscreener.com
Checkpoint (CKPT) Shares Skyrocket After A Takeover Agreement - Stocks Telegraph
Checkpoint Therapeutics Shares Leap Premarket on Takeover by Sun Pharma -March 10, 2025 at 06:24 am EDT - Marketscreener.com
Sun Pharma Pays 66% Premium in $355M Checkpoint Therapeutics Acquisition - Stock Titan
Checkpoint Therapeutics to Be Acquired by India's Sun Pharmaceutical -March 10, 2025 at 04:50 am EDT - Marketscreener.com
Sun Pharma to acquire Nasdaq-listed Checkpoint Therapeutics for $355 million; shares edge higher - Mint
Sun Pharma to acquire US based onco-derma firm Checkpoint for $355 mn - Business Standard
Sun Pharma to acquire 100% stake in Nasdaq-listed Checkpoint Therapeutics - Business Standard
India's Sun Pharma to acquire Checkpoint Therapeutics for $355 million - Reuters
India's Sun Pharma to acquire Checkpoint Therapeutics for $355 million -March 09, 2025 at 11:49 pm EDT - Marketscreener.com
Sun Pharma to Acquire Checkpoint Therapeutics - Quantisnow
India’s Sun Pharma to buy Checkpoint Therapeutics for $355 mln By Investing.com - Investing.com Australia
India’s Sun Pharma to buy Checkpoint Therapeutics for $355 mln - Investing.com
Sun Pharma to acquire Checkpoint Therapeutics for Rs 3,000 crore - Business Upturn
Mustang Bio meets Nasdaq’s equity listing requirements By Investing.com - Investing.com South Africa
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement - The Manila Times
Fortress Biotech, Inc. (NASDAQ:FBIOP) Short Interest Down 78.3% in February - Defense World
Mustang Bio Announces Sale of Fixed Assets and Exit of Facility - GlobeNewswire
Trading (FBIOP) With Integrated Risk Controls - news.stocktradersdaily.com
FDA extends review of Fortress Biotech's CUTX-101 drug - MSN
Is Fortress Biotech Inc (NASDAQ: FBIO) Still Hot This Week? - Stocks Register
(FBIOP) On The My Stocks Page - Stock Traders Daily
Buying Buzz: Fortress Biotech Inc [FBIO] PRESIDENT, CEO & CHAIRMAN ROSENWALD LINDSAY A MD purchases 763,359 shares of the company – Knox Daily - Knox Daily
Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement - The Manila Times
Mustang Bio Closes $8 Million Public Offering - citybiz
Mustang Bio Announces Closing of $8 Million Public Offering - GlobeNewswire
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):